Table 5.
Challenge Compound | Therapy | n | MLD (mg/kg) | 95% Confidence Interval | Probit Slope | PR1 | p value1 |
---|---|---|---|---|---|---|---|
Aldicarb | Saline/Saline | 36 | 0.86 | (0.74, 1.51) | 18 | N/A | N/A |
Atropine/Saline | 30 | 2.82 | (2.43, 3.46) | 15 | 3.30 | <0.0001 | |
2-PAM/Saline | 30 | 1.15 | (0.96, 1.39) | 10 | 1.34 | 0.003 | |
Atropine/2-PAM | 30 | 2.31 | (1.45, 5.74) | 3.0 | 2.70 | <0.0001 | |
Methomyl | Saline/Saline | 36 | 8.06 | (7.07, 8.97) | 18 | N/A | N/A |
Atropine/Saline | 30 | 15.20 | (9.49, 23.94) | 4.0 | 1.89 | 0.0003 | |
2-PAM/Saline | 30 | 9.22 | (6.68, 10.79) | 12 | 1.14 | 0.0683 | |
Atropine/2-PAM | 30 | 22.95 | (17.62, 27.87) | 13 | 2.85 | <0.0001 |
Protective ratio, the shift in the MLD between treatment groups, compared to Saline/Saline treated animals